Picking a PI in MM: Asking & Answering the W5 – Twitter Chat Evaluation (ID: i748-5) Question Title * 1. How many years have you been in practice? >21 11-20 1-10 <1 Question Title * 2. How many patients with MM do you treat each week? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 3. Please select the option that best describes your practice: Academic Clinician Community Clinician Other (please specify) Question Title * 4. Of the patients you will see in the next week, about how many will benefit from the information you learned today? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 5. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply. Apply safety and efficacy data for FDA-approved therapies for treatment selection in RRMM Utilize PI-based combination regimens in high-risk RRMM patients Improved risk stratification based on labs, imaging, and/or cytogenetics Employ patient-centered care including shared-decision making strategies Question Title * 6. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes Question Title * 7. After participating in this activity, I am now able to: Strongly agree Agree Neutral Disagree Strongly disagree Employ patient-focused strategies to improve outcomes among patients with multiple myeloma Employ patient-focused strategies to improve outcomes among patients with multiple myeloma Strongly agree Employ patient-focused strategies to improve outcomes among patients with multiple myeloma Agree Employ patient-focused strategies to improve outcomes among patients with multiple myeloma Neutral Employ patient-focused strategies to improve outcomes among patients with multiple myeloma Disagree Employ patient-focused strategies to improve outcomes among patients with multiple myeloma Strongly disagree Assess disparities in the treatment of multiple myeloma Assess disparities in the treatment of multiple myeloma Strongly agree Assess disparities in the treatment of multiple myeloma Agree Assess disparities in the treatment of multiple myeloma Neutral Assess disparities in the treatment of multiple myeloma Disagree Assess disparities in the treatment of multiple myeloma Strongly disagree Compare frailty indexes, scores and scales when evaluating patients with multiple myeloma Compare frailty indexes, scores and scales when evaluating patients with multiple myeloma Strongly agree Compare frailty indexes, scores and scales when evaluating patients with multiple myeloma Agree Compare frailty indexes, scores and scales when evaluating patients with multiple myeloma Neutral Compare frailty indexes, scores and scales when evaluating patients with multiple myeloma Disagree Compare frailty indexes, scores and scales when evaluating patients with multiple myeloma Strongly disagree Question Title * 8. The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Question Title * 9. This activity was free from commercial bias. Yes No Question Title * 10. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 12. What barriers do you see to making changes in your practice? Please select all that apply. Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement, or legal issues Conflicting guidelines and/or evidence Patient compliance and/or patient resource barriers Other (please specify) Question Title * 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities: Done